This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Why Testogel®?

Efficacy

Testogel® restores testosterone to within the normal range. Normal testosterone levels were achieved at day 182 in 82.2% (139/169) of hypogonadal men treated with an optimised dose, in a randomised placebo-controlled trial involving 274 patients.1

Physical

Kaufman et al evaluated the efficacy of titrated doses of Testogel® in 274 testosterone deficient men* who applied the gel daily for 182 days.1

Efficacy

  • Following titration, significantly more subjects receiving active treatment (range 81.6% to 82.5%) had testosterone values within the eugonadal range compared with placebo (range 28.6% to 37.0%) on all study days (p< 0.0001)

Safety

  • A similar percentage of serious treatment-emergent adverse events (TEAEs) occurred in the Testogel® (2.1%) and placebo groups (2.5%)

*Inclusion criteria: 18 to 80 years of age; Morning total testosterone < 10.4 nmol/L; Body Mass Index: 18 kg/m2 to 40 kg/m2

Testogel® restores testosterone levels to within the normal range

Efficacy graph

Adapted from Kaufman JM, et al.1

Quality of life

The time required for testosterone therapy (TTh) to improve symptoms of testosterone deficiency (TD) varies (dependent on the organ/process that is affected) but positive effects start within just 3–4 weeks and can start to have an impact on the day-to-day lives of patients. Such effects include (vs. baseline):2,3

Increased:

  • Muscle mass
  • Exercise capacity

Decreased:

  • Fat mass
  • Waist circumference

Increased:

  • Erectile function
  • Morning erections
  • Sexual activity/ejaculations

 

  • Sexual interest and desire
  • Satisfaction with sex life

For further details regarding the efficacy time frames associated with alleviation of symptoms refer to time to symptom improvement.

References

  1. Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8(7):2079–2089.
  2. Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71(3–4).
  3. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.

TES/2022/046. February 2023.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: pharmacovigilance@besins-healthcare.com